GSK And Merck Accelerate R&D In Japan
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline and Merck are speeding up research and development in Japan. This month, GSK Japan established an R&D center to tackle orphan diseases such as duchenne muscular dystrophy, for which the company plans to commence clinical trails soon. GSK Japan President Mark Dunoyer said the company is aiming for a fast launch of treatments for the rare disease